The Readout Loud

STAT

Wirtschaft

Neueste Episode

Verfügbare Folgen

5 von 378

374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market
On this week’s episode of “The Readout LOUD”: an interview with veteran biotech executive and company founder Clive Meanwell. Pfizer recently acquired one of Meanwell’s companies, the obesity drug developer Metsera, for just under $5 billion. Meanwell offered his perspectives on the evolving obesity drug market, and continued need for drugs to treat diseases with large prevalence, which he’s doing with his latest venture, called Corsera Health. Meanwell also weighed in on drug pricing policies both in the U.S. and the U.K. Your favorite podcast co-hosts have been extra busy this week moderating panel discussions at the STAT Summit in Boston, so we prerecorded this interview with Meanwell on Oct. 8. A regular “Readout LOUD” episode will return next week.
--------
34:10
--------
34:10
373: Party in biotech land and AstraZeneca’s miscalculation
Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on Mizuho health care strategist Jared Holz to discuss the rebound in biotech stocks and sentiment. We also talk about Marks’ new role at Eli Lilly after leaving the Food and Drug Administration, an attempt by a biotech to revive a rare disease drug shelved by AstraZeneca, and new funds raised by China-focused Expedition Therapeutics.
--------
45:40
--------
45:40
372: A pharma C-suite shakeup and Trump's deal with Pfizer
How will we look back on Emma Walmsley's tenure as GSK's CEO? Why did one of the FDA's top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff?Adam is out this week, so Allison and Elaine dive into the latest news, starting with another biotech acquisition and a new CEO at GSK. Then, they invite health policy researcher Stacie Dusetzina to break down President Trump's "most-favored nation" pricing deal with Pfizer.
--------
28:05
--------
28:05
371: A gene therapy success in Huntington's and Trump's autism announcement
We bring on UniQure CEO Matt Kapusta to discuss the company's announcement this week that its one-time treatment for Huntington’s disease significantly slowed down the neurological condition in a key study. We also chat about the Trump's administration initiatives on autism. Officials this week warned pregnant women not to take Tylenol, saying that it may cause autism, and they announced an FDA decision to make a decades-old drug called leucovorin available as a treatment for people with certain autism symptoms. To unpack the implications of these statements, we bring on by Ari Ne'eman, an assistant professor of health policy and management at Harvard’s school of public health who researches how policies affect people with disabilities.
--------
42:32
--------
42:32
370: Pharma sours on the U.K., plus biotech M&A's quiet roll
STAT's European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money elsewhere. We also discuss the Advisory Committee on Immunization Practices, or ACIP, meeting and biotech M&A, including Roche's $3.5 billion acquisition of 89bio and its MASH drug, announced this week.
--------
37:21
--------
37:21